CARL ZEISS MEDITEC AG - BR (AFX.DE) Stock Fundamental Analysis
Europe - FRA:AFX - DE0005313704 - Common Stock
42.56 EUR
+0.96 (+2.31%)
Overall AFX gets a fundamental rating of 4 out of 10. We evaluated AFX against 60 industry peers in the Health Care Equipment & Supplies industry. AFX has an average financial health and profitability rating. While showing a medium growth rate, AFX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year AFX was profitable.
In the past year AFX had a positive cash flow from operations.
In the past 5 years AFX has always been profitable.
AFX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 4.49%, AFX is in the better half of the industry, outperforming 63.33% of the companies in the same industry.
AFX has a Return On Equity (7.51%) which is in line with its industry peers.
AFX has a Return On Invested Capital (4.74%) which is in line with its industry peers.
The Average Return On Invested Capital over the past 3 years for AFX is in line with the industry average of 8.99%.
The last Return On Invested Capital (4.74%) for AFX is well below the 3 year average (9.30%), which needs to be investigated, but indicates that AFX had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.49% | ||
| ROE | 7.51% | ||
| ROIC | 4.74% |
ROA(3y)8.42%
ROA(5y)8.24%
ROE(3y)12.26%
ROE(5y)11.91%
ROIC(3y)9.3%
ROIC(5y)9.86%
1.3 Margins
AFX's Profit Margin of 7.19% is in line compared to the rest of the industry. AFX outperforms 53.33% of its industry peers.
AFX's Profit Margin has declined in the last couple of years.
The Operating Margin of AFX (8.55%) is comparable to the rest of the industry.
In the last couple of years the Operating Margin of AFX has declined.
AFX has a Gross Margin (52.43%) which is in line with its industry peers.
In the last couple of years the Gross Margin of AFX has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.55% | ||
| PM (TTM) | 7.19% | ||
| GM | 52.43% |
OM growth 3Y-25.26%
OM growth 5Y-12.3%
PM growth 3Y-15.52%
PM growth 5Y-4.6%
GM growth 3Y-3.56%
GM growth 5Y-1.56%
2. Health
2.1 Basic Checks
AFX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
AFX has less shares outstanding than it did 1 year ago.
The number of shares outstanding for AFX has been reduced compared to 5 years ago.
AFX has a worse debt/assets ratio than last year.
2.2 Solvency
AFX has an Altman-Z score of 3.23. This indicates that AFX is financially healthy and has little risk of bankruptcy at the moment.
AFX has a Altman-Z score of 3.23. This is in the better half of the industry: AFX outperforms 65.00% of its industry peers.
AFX has a debt to FCF ratio of 7.17. This is a slightly negative value and a sign of low solvency as AFX would need 7.17 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 7.17, AFX is in line with its industry, outperforming 48.33% of the companies in the same industry.
AFX has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of AFX (0.27) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 7.17 | ||
| Altman-Z | 3.23 |
ROIC/WACC0.69
WACC6.83%
2.3 Liquidity
A Current Ratio of 2.04 indicates that AFX has no problem at all paying its short term obligations.
AFX's Current ratio of 2.04 is in line compared to the rest of the industry. AFX outperforms 60.00% of its industry peers.
A Quick Ratio of 1.17 indicates that AFX should not have too much problems paying its short term obligations.
AFX has a Quick ratio (1.17) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.04 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
AFX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.00%.
The Earnings Per Share has been growing slightly by 2.35% on average over the past years.
Looking at the last year, AFX shows a small growth in Revenue. The Revenue has grown by 5.50% in the last year.
The Revenue has been growing slightly by 7.20% on average over the past years.
EPS 1Y (TTM)-25%
EPS 3Y-8.8%
EPS 5Y2.35%
EPS Q2Q%-15.79%
Revenue 1Y (TTM)5.5%
Revenue growth 3Y7.85%
Revenue growth 5Y7.2%
Sales Q2Q%1.92%
3.2 Future
The Earnings Per Share is expected to grow by 13.55% on average over the next years. This is quite good.
The Revenue is expected to grow by 6.84% on average over the next years.
EPS Next Y-13.79%
EPS Next 2Y1.48%
EPS Next 3Y8.03%
EPS Next 5Y13.55%
Revenue Next Year6.32%
Revenue Next 2Y5.61%
Revenue Next 3Y6.13%
Revenue Next 5Y6.84%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
AFX is valuated rather expensively with a Price/Earnings ratio of 24.89.
Compared to the rest of the industry, the Price/Earnings ratio of AFX indicates a somewhat cheap valuation: AFX is cheaper than 70.00% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 25.51. AFX is around the same levels.
A Price/Forward Earnings ratio of 20.56 indicates a rather expensive valuation of AFX.
The rest of the industry has a similar Price/Forward Earnings ratio as AFX.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.98, AFX is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.89 | ||
| Fwd PE | 20.56 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AFX is valued a bit cheaper than the industry average as 70.00% of the companies are valued more expensively.
AFX's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 45.89 | ||
| EV/EBITDA | 12.5 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)10.61
EPS Next 2Y1.48%
EPS Next 3Y8.03%
5. Dividend
5.1 Amount
AFX has a Yearly Dividend Yield of 1.38%.
Compared to an average industry Dividend Yield of 2.11, AFX pays a bit more dividend than its industry peers.
With a Dividend Yield of 1.38, AFX pays less dividend than the S&P500 average, which is at 2.44.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.38% |
5.2 History
On average, the dividend of AFX grows each year by 15.07%, which is quite nice.
Dividend Growth(5Y)15.07%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
33.69% of the earnings are spent on dividend by AFX. This is a low number and sustainable payout ratio.
The dividend of AFX is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP33.69%
EPS Next 2Y1.48%
EPS Next 3Y8.03%
FRA:AFX (11/19/2025, 4:46:39 PM)
42.56
+0.96 (+2.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners22.55%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.81B
Revenue(TTM)2.18B
Net Income(TTM)155.89M
Analysts73.64
Price Target55.56 (30.55%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.38% |
Yearly Dividend1.11
Dividend Growth(5Y)15.07%
DP33.69%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.71%
Min EPS beat(2)-36.67%
Max EPS beat(2)13.25%
EPS beat(4)2
Avg EPS beat(4)-5.53%
Min EPS beat(4)-36.67%
Max EPS beat(4)37.18%
EPS beat(8)6
Avg EPS beat(8)8.89%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)2.29%
Min Revenue beat(2)0.82%
Max Revenue beat(2)3.76%
Revenue beat(4)3
Avg Revenue beat(4)0.58%
Min Revenue beat(4)-2.4%
Max Revenue beat(4)3.76%
Revenue beat(8)5
Avg Revenue beat(8)-0.67%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.25%
PT rev (3m)-15.67%
EPS NQ rev (1m)-4.88%
EPS NQ rev (3m)-4.88%
EPS NY rev (1m)0.62%
EPS NY rev (3m)-9.15%
Revenue NQ rev (1m)-0.2%
Revenue NQ rev (3m)-0.2%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)-0.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.89 | ||
| Fwd PE | 20.56 | ||
| P/S | 1.75 | ||
| P/FCF | 45.89 | ||
| P/OCF | 19.46 | ||
| P/B | 1.83 | ||
| P/tB | 9.81 | ||
| EV/EBITDA | 12.5 |
EPS(TTM)1.71
EY4.02%
EPS(NY)2.07
Fwd EY4.86%
FCF(TTM)0.93
FCFY2.18%
OCF(TTM)2.19
OCFY5.14%
SpS24.26
BVpS23.21
TBVpS4.34
PEG (NY)N/A
PEG (5Y)10.61
Graham Number29.88
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.49% | ||
| ROE | 7.51% | ||
| ROCE | 6.52% | ||
| ROIC | 4.74% | ||
| ROICexc | 4.83% | ||
| ROICexgc | 12.2% | ||
| OM | 8.55% | ||
| PM (TTM) | 7.19% | ||
| GM | 52.43% | ||
| FCFM | 3.82% |
ROA(3y)8.42%
ROA(5y)8.24%
ROE(3y)12.26%
ROE(5y)11.91%
ROIC(3y)9.3%
ROIC(5y)9.86%
ROICexc(3y)9.4%
ROICexc(5y)9.95%
ROICexgc(3y)15.11%
ROICexgc(5y)14.88%
ROCE(3y)12.78%
ROCE(5y)13.55%
ROICexgc growth 3Y-11.32%
ROICexgc growth 5Y-4.98%
ROICexc growth 3Y-28.53%
ROICexc growth 5Y-15.45%
OM growth 3Y-25.26%
OM growth 5Y-12.3%
PM growth 3Y-15.52%
PM growth 5Y-4.6%
GM growth 3Y-3.56%
GM growth 5Y-1.56%
F-Score4
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 7.17 | ||
| Debt/EBITDA | 1.68 | ||
| Cap/Depr | 73.33% | ||
| Cap/Sales | 5.19% | ||
| Interest Coverage | 13.7 | ||
| Cash Conversion | 57.69% | ||
| Profit Quality | 53.21% | ||
| Current Ratio | 2.04 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 3.23 |
F-Score4
WACC6.83%
ROIC/WACC0.69
Cap/Depr(3y)128.62%
Cap/Depr(5y)113.53%
Cap/Sales(3y)5.71%
Cap/Sales(5y)4.9%
Profit Quality(3y)45.51%
Profit Quality(5y)74.23%
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3Y-8.8%
EPS 5Y2.35%
EPS Q2Q%-15.79%
EPS Next Y-13.79%
EPS Next 2Y1.48%
EPS Next 3Y8.03%
EPS Next 5Y13.55%
Revenue 1Y (TTM)5.5%
Revenue growth 3Y7.85%
Revenue growth 5Y7.2%
Sales Q2Q%1.92%
Revenue Next Year6.32%
Revenue Next 2Y5.61%
Revenue Next 3Y6.13%
Revenue Next 5Y6.84%
EBIT growth 1Y-40.66%
EBIT growth 3Y-19.39%
EBIT growth 5Y-5.98%
EBIT Next Year57.06%
EBIT Next 3Y26.22%
EBIT Next 5Y19.92%
FCF growth 1Y-30.57%
FCF growth 3Y-31.55%
FCF growth 5Y-11.27%
OCF growth 1Y-1.41%
OCF growth 3Y-11.98%
OCF growth 5Y2.4%
CARL ZEISS MEDITEC AG - BR / AFX.DE FAQ
What is the fundamental rating for AFX stock?
ChartMill assigns a fundamental rating of 4 / 10 to AFX.DE.
Can you provide the valuation status for CARL ZEISS MEDITEC AG - BR?
ChartMill assigns a valuation rating of 3 / 10 to CARL ZEISS MEDITEC AG - BR (AFX.DE). This can be considered as Overvalued.
Can you provide the profitability details for CARL ZEISS MEDITEC AG - BR?
CARL ZEISS MEDITEC AG - BR (AFX.DE) has a profitability rating of 5 / 10.
What is the valuation of CARL ZEISS MEDITEC AG - BR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CARL ZEISS MEDITEC AG - BR (AFX.DE) is 24.89 and the Price/Book (PB) ratio is 1.83.
What is the financial health of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?
The financial health rating of CARL ZEISS MEDITEC AG - BR (AFX.DE) is 5 / 10.